GSK’s Clinical Development Plan For Jemperli In Rectal Cancer Draws US FDA Concerns

 
• By Sue Sutter
Horizon
GSK is seeking to expand dostarlimab's indication horizon with studies in rectal cancer. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers